HK1202154A1 - Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment - Google Patents

Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment Download PDF

Info

Publication number
HK1202154A1
HK1202154A1 HK15102546.8A HK15102546A HK1202154A1 HK 1202154 A1 HK1202154 A1 HK 1202154A1 HK 15102546 A HK15102546 A HK 15102546A HK 1202154 A1 HK1202154 A1 HK 1202154A1
Authority
HK
Hong Kong
Prior art keywords
prediction
coronary artery
artery disease
patients undergoing
disease patients
Prior art date
Application number
HK15102546.8A
Other languages
English (en)
Chinese (zh)
Inventor
Reijo Laaksonen
Kim Ekroos
Reini Hurme
Minna Jänis
Riikka Katainen
Kirill Tarasov
Original Assignee
Zora Biosciences Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zora Biosciences Oy filed Critical Zora Biosciences Oy
Publication of HK1202154A1 publication Critical patent/HK1202154A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/0027—Methods for using particle spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15102546.8A 2011-11-08 2012-11-07 Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment HK1202154A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161556915P 2011-11-08 2011-11-08
US61/556,915 2011-11-08
EP11188325.2 2011-11-08
EP11188325.2A EP2592422A1 (en) 2011-11-08 2011-11-08 Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
PCT/EP2012/071973 WO2013068374A2 (en) 2011-11-08 2012-11-07 Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment

Publications (1)

Publication Number Publication Date
HK1202154A1 true HK1202154A1 (en) 2015-09-18

Family

ID=45033776

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102546.8A HK1202154A1 (en) 2011-11-08 2012-11-07 Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment

Country Status (7)

Country Link
US (3) US9052327B2 (enExample)
EP (2) EP2592422A1 (enExample)
JP (1) JP6388284B2 (enExample)
CN (1) CN104024860B (enExample)
CA (1) CA2854422A1 (enExample)
HK (1) HK1202154A1 (enExample)
WO (1) WO2013068374A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9806270B2 (en) 2011-03-25 2017-10-31 Udc Ireland Limited 4H-imidazo[1,2-a]imidazoles for electronic applications
EP2592423A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
CN108440531B (zh) 2011-11-10 2021-11-02 Udc 爱尔兰有限责任公司 用于电子应用的4H-咪唑并[1,2-a]咪唑
EP2667197B1 (en) * 2012-05-25 2015-09-16 Zora Biosciences OY Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
US9620724B2 (en) 2012-07-10 2017-04-11 Udc Ireland Limited Benzimidazo[1,2-A]benzimidazole derivatives for electronic applications
BR112016023418A8 (pt) 2014-04-10 2019-12-10 MEP Equine Solutions LLC método e kit para a quantificação de ovos de parasitas nas fezes
US9347960B2 (en) 2014-06-16 2016-05-24 Zora Biosciences, Oy Ceramides and their use in diagnosing CVD
WO2016100549A2 (en) * 2014-12-16 2016-06-23 Washington University Ceramides for evaluating risk of cardiovascular disease
US10184932B2 (en) 2015-12-07 2019-01-22 Zora Biosciences Oy Use of ceramides and LPLs in diagnosing CVD
CN105424841B (zh) * 2015-12-25 2017-11-03 齐炼文 用于诊断冠状动脉粥样硬化的代谢标志物
CN105486773A (zh) * 2015-12-25 2016-04-13 齐炼文 用于诊断冠心病的代谢标志物
CN105628809B (zh) * 2015-12-25 2018-04-03 中国药科大学 用于诊断区分冠状动脉粥样硬化和冠心病的代谢标志物
KR102003309B1 (ko) * 2016-12-05 2019-07-25 한국과학기술연구원 대사체 및 임상지표를 활용한 관상동맥 심장질환 진단용 키트 및 기초 정보 제공 방법
CN107144648B (zh) * 2017-04-26 2019-11-22 苏州海科医药技术有限公司 检测人血浆中匹伐他汀的液相色谱-串联质谱方法
CN107014942A (zh) * 2017-05-05 2017-08-04 北京骐骥生物技术有限公司 利用脂质生物标志物预测糖尿病冠心病的方法
WO2019119049A1 (en) * 2017-12-20 2019-06-27 Baker Heart and Diabetes Institute Method of predicting drug therapeutic responder status and methods of treatment
US12441815B2 (en) 2018-11-02 2025-10-14 The Regents Of The University Of California Compositions and methods for diagnosis of cardiovascular disease
WO2020112149A1 (en) * 2018-12-01 2020-06-04 Binhai Industrial Technology Research Institute Of Zhejiang University Methods and compositions for the assessment of acute myocardial infarction (ami)
WO2020115288A1 (en) 2018-12-06 2020-06-11 Zora Biosciences Oy Biomarkers for cardiovascular events
CN109828076B (zh) * 2019-04-11 2020-07-21 江南大学 一种高效薄层色谱联用生物发光法筛查贝特类降脂化学药掺伪的方法
CN112630344B (zh) * 2020-12-08 2021-12-14 河北医科大学第二医院 代谢标志物在脑梗死中的用途
CN113533754A (zh) * 2021-07-12 2021-10-22 北京市心肺血管疾病研究所 神经酰胺在制备用于评估高血压患者发生不良事件风险的试剂盒中的应用
CN113567583B (zh) * 2021-07-22 2022-06-07 江南大学 应用固相萃取-超临界流体色谱-质谱法检测乳中极性脂的方法
CN116087486B (zh) * 2021-11-08 2024-02-02 中国医学科学院阜外医院 糖尿病患者早期预测心血管疾病（cvd）的生物标志物及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210976B1 (en) * 1997-06-10 2001-04-03 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
WO2004038381A2 (en) 2002-10-25 2004-05-06 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US7972802B2 (en) 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease
US8137977B2 (en) * 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
DE102006034153B4 (de) 2006-07-24 2018-02-08 Magna powertrain gmbh & co kg Getriebe
US20100179066A1 (en) 2007-06-07 2010-07-15 Inserm (Institut National De La Santé Et De La Rec Method for Assessing the Risk of a Cardiovascular Disease and for Diagnosing Dyslipidemia
EP2048243A1 (en) 2007-09-24 2009-04-15 sanofi-aventis Use of clec1B for the determination of cardiovascular and thrombotic risk
ES2374762T3 (es) * 2007-10-10 2012-02-21 Bg Medicine, Inc. Procedimientos para detectar complicaciones cardiovasculares y cerebrovasculares adversas graves.
GB2469244A (en) * 2008-01-28 2010-10-06 Univ Singapore Lipid tumour profile
AU2009224114B2 (en) 2008-03-12 2013-02-21 Otago Innovation Limited Biomarkers
CN102037014A (zh) * 2008-03-12 2011-04-27 奥塔哥创新有限公司 生物标记物
CN102203606A (zh) 2008-10-30 2011-09-28 公共健康研究中心 生物标记物
US20110034419A1 (en) * 2009-06-27 2011-02-10 Musc Foundation For Research Development Cardioprotective Drugs and Diagnostics for Assessing Risk of Cardiovascular Disease
EP2502068B1 (en) * 2009-11-17 2016-02-10 Baylor Research Institute Urinary triaosylceramide (gb3) as a marker of cardiac disease
US9110086B2 (en) 2009-11-27 2015-08-18 Baker Idi Heart And Diabetes Institute Holdings Limited Lipid biomarkers for stable and unstable heart disease
ES2455124T5 (es) 2010-05-05 2018-05-08 Zora Biosciences Oy Biomarcadores lipidómicos para la aterosclerosis y afección cardíaca
CN103154742B (zh) * 2010-06-20 2017-11-21 佐拉生物科学公司 用于鉴定高风险冠状动脉疾病患者的脂质组学标志
EP2400573A1 (de) 2010-06-23 2011-12-28 Bayer MaterialScience AG Elektromechanischer Wandler, Verfahren zu dessen Herstellung und Verwendung desselben
US9664698B2 (en) 2011-04-08 2017-05-30 Zora Biosciences Oy Biomarkers for sensitive detection of statin-induced muscle toxicity
FI20115576A0 (fi) * 2011-06-10 2011-06-10 Teknologian Tutkimuskeskus Vtt Oy Menetelmä Alzheimerin taudin diagnoimiseksi
EP2592423A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment

Also Published As

Publication number Publication date
WO2013068374A2 (en) 2013-05-16
EP2776842A2 (en) 2014-09-17
CA2854422A1 (en) 2013-05-16
US9052327B2 (en) 2015-06-09
CN104024860A (zh) 2014-09-03
EP2776842B1 (en) 2017-07-12
US20140295466A1 (en) 2014-10-02
CN104024860B (zh) 2017-06-06
US20150260738A1 (en) 2015-09-17
EP2592422A1 (en) 2013-05-15
US20160363602A1 (en) 2016-12-15
JP6388284B2 (ja) 2018-09-12
US9459265B2 (en) 2016-10-04
JP2014532886A (ja) 2014-12-08
WO2013068374A3 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
WO2013068374A3 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
WO2013068373A3 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
WO2011161062A3 (en) Lipidomic biomarkers for identification of high-risk coronary artery disease patients
NZ602056A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011142827A3 (en) Diagnostic markers for neuropsychiatric disease
NZ597273A (en) Trimethylamine-containing compounds for diagnosis and prediction of disease
WO2013190075A3 (en) Specific biomarkers for hepatocellular carcinoma (hcc)
WO2014037588A3 (en) Methods and compounds for preventing, treating and diagnosing an inflammatory condition
WO2009077864A3 (en) Compositions and methods of detecting tiabs
WO2012149493A3 (en) Hsp90 combination therapy
WO2012174282A3 (en) Biomarker compositions and methods
PH12022550310A1 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ECSP088081A (es) Detección de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapéutico correspondiente
NZ609824A (en) Immunochromatography devices, methods and kits
Leung et al. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies
EP2569635A4 (en) METHOD FOR DIAGNOSIS AND / OR TREATMENT OF ENZEPHALITIS OR EPILEPSY
WO2009019367A3 (fr) Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
WO2014053996A3 (en) Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs
WO2012050365A3 (ko) 교모세포종의 진단 또는 예후 예측용 바이오 마커 및 그 용도
EA200802242A1 (ru) Способ определения того, будет или не будет пациент респондером на иммунотерапию
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
WO2015006657A3 (en) Method for the diagnosis and prognosis of cancer
WO2012101219A3 (en) Complex mirna sets as novel biomarkers for lung diseases
WO2013167727A3 (en) Method for determining arthritis relapse risk